Western Wealth Management LLC Grows Stock Position in Stryker Corporation $SYK

Western Wealth Management LLC increased its stake in Stryker Corporation (NYSE:SYK) by 55.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,592 shares of the medical technology company’s stock after buying an additional 1,633 shares during the quarter. Western Wealth Management LLC’s holdings in Stryker were worth $1,817,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Mid American Wealth Advisory Group Inc. bought a new position in Stryker during the 2nd quarter valued at about $26,000. Sachetta LLC boosted its position in shares of Stryker by 58.7% during the second quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock valued at $29,000 after buying an additional 27 shares during the period. Ridgewood Investments LLC grew its stake in shares of Stryker by 48.4% during the second quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company’s stock valued at $36,000 after buying an additional 30 shares during the last quarter. MTM Investment Management LLC purchased a new stake in shares of Stryker in the second quarter worth approximately $38,000. Finally, Ransom Advisory Ltd bought a new position in Stryker in the 1st quarter valued at $37,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Transactions at Stryker

In related news, Director Ronda E. Stryker sold 276,173 shares of the company’s stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $353.28, for a total value of $97,566,397.44. Following the completion of the transaction, the director owned 2,702,108 shares of the company’s stock, valued at approximately $954,600,714.24. This represents a 9.27% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Viju Menon sold 500 shares of the stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the transaction, the insider owned 12,511 shares in the company, valued at $4,886,921.71. This represents a 3.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 520,500 shares of company stock worth $184,803,065 over the last 90 days. Insiders own 5.90% of the company’s stock.

Stryker Trading Down 0.8%

Shares of NYSE:SYK opened at $359.37 on Monday. The business’s 50-day moving average is $371.96 and its 200 day moving average is $381.27. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. Stryker Corporation has a 1 year low of $329.16 and a 1 year high of $406.19. The firm has a market capitalization of $137.43 billion, a P/E ratio of 47.70, a P/E/G ratio of 2.66 and a beta of 0.94.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share for the quarter, topping analysts’ consensus estimates of $3.13 by $0.06. The business had revenue of $6.06 billion for the quarter, compared to analyst estimates of $6.04 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The company’s revenue was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.87 earnings per share. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. On average, research analysts predict that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

SYK has been the subject of several research analyst reports. Evercore ISI decreased their target price on Stryker from $410.00 to $405.00 and set an “outperform” rating for the company in a research report on Friday, October 31st. BTIG Research reissued a “buy” rating and issued a $410.00 price objective on shares of Stryker in a research note on Friday. Barclays lifted their target price on Stryker from $443.00 to $453.00 and gave the company an “overweight” rating in a research report on Wednesday, October 22nd. Weiss Ratings restated a “hold (c+)” rating on shares of Stryker in a research note on Thursday. Finally, Truist Financial upped their price objective on shares of Stryker from $392.00 to $400.00 and gave the stock a “hold” rating in a research note on Friday. Thirteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $434.37.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.